Dalbavancin

Description

1. Product Overview

Dalbavancin is a next-generation lipoglycopeptide antibiotic indicated for acute bacterial skin and skin structure infections (ABSSSI). Its primary industrial use is as an active pharmaceutical ingredient (API) in sterile injectable formulations. The key value proposition is a two-dose, once-weekly regimen that improves patient adherence and reduces hospitalization costs. Strategically, it addresses growing demand for long-acting antibiotics amid rising antimicrobial resistance and outpatient care models.

2. Key Specifications & Technical Characteristics

• Chemical composition: Lipoglycopeptide (C₈₈H₁₀₀Cl₂N₁₀O₂₈) – Dalbavancin base

• Purity grade: ≥ 98.0% (HPLC), residual solvents per ICH Q3C

• Physical characteristics: White to off-white lyophilized powder or crystalline solid; particle size D90 ≤ 50 µm (micronized available)

• Density: Bulk density 0.35–0.55 g/cm³

• Packaging options: Double-laminated polyethylene bags in HDPE drums (1 kg, 5 kg, 10 kg); or custom sterile single-use containers for aseptic processing

• Shelf life: 36 months when stored at 2–8°C, protected from light

3. Core Industrial Applications

• Primary industries: Pharmaceutical manufacturing (branded & generic injectables); CDMOs (contract development and manufacturing organizations); hospital compounding pharmacies

• Specific use cases:

  • Commercial production of lyophilized vials (500 mg) for ABSSSI treatment

  • Development of once-weekly long-acting parenteral formulations

  • Salvage therapy for methicillin-resistant Staphylococcus aureus (MRSA)

• Why it performs better: Dual mechanism (inhibition of cell wall synthesis & disruption of membrane potential) ensures potency against resistant Gram-positive pathogens. Superior pharmacokinetics allow extended dosing interval, reducing total infusion events by >80% compared to vancomycin or daptomycin.

• Commercial advantage: Lower total cost of therapy via reduced hospitalization and nursing administration time.

4. Competitive Advantages

• Quality consistency: Batch-to-batch reproducibility with ≤ 0.5% RSD for potency; full traceability to USP/EP reference standards

• Supply reliability: Multi-site cGMP manufacturing (FDA, EMA, WHO audited); 12-month rolling forecast commitment available

• Logistics capability: Cold chain validated with real-time temperature monitoring (2–8°C, 72-hour excursion tolerance up to 25°C)

• Price competitiveness: Tiered pricing for volumes ≥ 20 kg; direct manufacturer contract eliminates distributor markups

• Sustainability: Solvent recovery rate ≥ 85% in synthesis; reduced cold chain carbon footprint via passive thermal packaging

• Technical support: Dedicated regulatory dossier (DMF Type II) and stability data package provided under confidentiality agreement.

5. Commercial & Supply Information

• Minimum order quantity (MOQ) : 1 kg for initial qualification; 5 kg for standard replenishment

• BULK 20MT: Not applicable – pharmaceutical API supplied in kg scale

• Loading capacity per container: 20’ reefer container – up to 2,500 kg (palletized, 2–8°C)